Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Veracyte (VCYT) over the last 13 years, with Q3 2025 value amounting to $956000.0.

  • Veracyte's Other Working Capital Changes rose 16446.39% to $956000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $39.6 million, marking a year-over-year increase of 88696.86%. This contributed to the annual value of -$5.4 million for FY2024, which is 2487.3% down from last year.
  • Latest data reveals that Veracyte reported Other Working Capital Changes of $956000.0 as of Q3 2025, which was up 16446.39% from $2.5 million recorded in Q2 2025.
  • Veracyte's Other Working Capital Changes' 5-year high stood at $33.2 million during Q4 2024, with a 5-year trough of -$5.8 million in Q3 2023.
  • Over the past 5 years, Veracyte's median Other Working Capital Changes value was $617000.0 (recorded in 2021), while the average stood at $1.6 million.
  • Over the last 5 years, Veracyte's Other Working Capital Changes had its largest YoY gain of 310452.49% in 2024, and its largest YoY loss of 87078.65% in 2024.
  • Over the past 5 years, Veracyte's Other Working Capital Changes (Quarter) stood at $1.4 million in 2021, then tumbled by 162.23% to -$878000.0 in 2022, then decreased by 25.85% to -$1.1 million in 2023, then surged by 3104.52% to $33.2 million in 2024, then plummeted by 97.12% to $956000.0 in 2025.
  • Its Other Working Capital Changes stands at $956000.0 for Q3 2025, versus $2.5 million for Q2 2025 and $2.9 million for Q1 2025.